Actively Recruiting
A First-in-Human Single and Multiple Ascending Dose Study of MT-701
Led by Mirador Therapeutics, Inc. · Updated on 2026-02-09
78
Participants Needed
1
Research Sites
37 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-701 in healthy participants.
CONDITIONS
Official Title
A First-in-Human Single and Multiple Ascending Dose Study of MT-701
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female participants aged 19 to 55 years (inclusive) at the time of consent
- Female participants must be of nonchildbearing potential, defined as postmenopausal or surgically sterile with official documentation at least 6 months before the first dose
- Male participants must use effective contraception during sex with female partners who can bear children; non-vasectomized males must use a condom with a chemical barrier method
- Participants must be in good general health
- Able to provide written informed consent and comply with study requirements
You will not qualify if you...
- History or presence of any clinically significant organ system disease
- Abnormal lab tests, physical exam, or ECG judged clinically significant by the investigator
- History of alcohol or drug abuse within the past 24 months
- Current or recent regular use of tobacco or nicotine products within 3 months before screening
- Use of any prescription drug within 21 days or over-the-counter drug within 7 days before study drug administration
- Use of any investigational drug or device within 30 days before the first dose
- Blood donation within 60 days or plasma donation within 14 days before dosing
- Sensitivity or allergy to study drugs or components, or any allergy contraindicating participation as judged by the investigator or medical monitor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mirador Clinical Department
San Diego, California, United States, 92121
Actively Recruiting
Research Team
T
Toll-Free Number
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here